Because of its role as an emerging leader in intranasal therapeutics --Javelin Pharmaceuticals (Amex: JAV) -- has received the 2006 Frost & Sullivan Award for Entrepreneurial Company of the Year.
The said award is granted each year by Frost & Sullivan to a company that has demonstrated superior entrepreneurial ability in its industry and signifies the company's identification of a unique and revolutionary product solution with significant market potential.
"Presently, Javelin Pharmaceuticals has two late-stage intranasal pain management products, Rylomine and PMI-100/150, in development. Rylomine™ is currently in Phase III clinical trials, and PMI-150 is in late phase II trials. 
According to Frost & Sullivan Research Analyst Jason McKinnie:
Read the full press release.Both products are reformulations of well-known, well-characterized drugs. Morphine is the active ingredient in Rylomine, and ketamine the active ingredient in PMI- 100/150.
Also in Phase III clinical trials is their lead product Dyloject™, an injectable nonselective NSAID for the treatment of postoperative pain."
Comment Preview